The purpose of this study is to establish a safe dose of autologous CD138-CAR-T cells to infuse after lymphodepletion in adult patients with relapsed / refractory multiple myeloma.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Sascha Tuchman
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Multiple Myeloma)
16-2216
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
